Enterotoxigenic Escherichia Coli (ETEC) is a type of
Escherichia coli and the leading bacterial cause of
diarrhea in the developing world, as well as the most common cause of
Traveler's diarrhea. Each year, approximately 210 million cases and 380,000 deaths occur, mostly in children, from ETEC. A number of
pathogenic isolates are termed ETEC, but the main hallmarks of this type of
bacteria are expression of one or more
enterotoxins and presence of
fimbriae used for attachment to host intestinal cells. Enterotoxins produced by ETEC include heat-labile (LT) enterotoxin and heat-stable (ST) enterotoxin. LT is similar to
cholera toxin; it increases the level of cAMP in intestinal cells, and this causes an increase in electrolyte and water excretion (diarrhea). ST stimulates production of cGMP, also leading to increased fluid excretion and diarrhea. Because enterotoxic
E. coli strains are non-invasive, they do not cause inflammation or bloody diarrhea. Infection with ETEC can cause profuse watery diarrhea and abdominal cramping. Fever, nausea with or without vomiting, chills, loss of appetite, headache, muscle aches and bloating can also occur but are less common.
Prevention and treatment
The most effective method of preventing
diarrhea due to ETEC is vaccination. However,
vaccines against ETEC are not yet available for populations where ETEC is endemic. There are currently available treatment options against
traveler's diarrhea, specifically against illness due to
cholera. Data from natural history studies of ETEC infections in children in developing countries suggest that immunization against ETEC early in life may be an effective preventive strategy. The
World Health Organization recommends further research into the development of a vaccine against ETEC. Treatment for ETEC infection includes rehydration therapy and antibiotics, although ETEC is frequently resistent to common antibiotics.
See also
References